JP2014503499A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014503499A5 JP2014503499A5 JP2013540060A JP2013540060A JP2014503499A5 JP 2014503499 A5 JP2014503499 A5 JP 2014503499A5 JP 2013540060 A JP2013540060 A JP 2013540060A JP 2013540060 A JP2013540060 A JP 2013540060A JP 2014503499 A5 JP2014503499 A5 JP 2014503499A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- ldh
- ldh5
- ldh4
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (21)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41514710P | 2010-11-18 | 2010-11-18 | |
| US41513610P | 2010-11-18 | 2010-11-18 | |
| US41513910P | 2010-11-18 | 2010-11-18 | |
| US41512210P | 2010-11-18 | 2010-11-18 | |
| US41515610P | 2010-11-18 | 2010-11-18 | |
| US41515510P | 2010-11-18 | 2010-11-18 | |
| US41515810P | 2010-11-18 | 2010-11-18 | |
| US61/415,139 | 2010-11-18 | ||
| US61/415,156 | 2010-11-18 | ||
| US61/415,147 | 2010-11-18 | ||
| US61/415,122 | 2010-11-18 | ||
| US61/415,155 | 2010-11-18 | ||
| US61/415,158 | 2010-11-18 | ||
| US61/415,136 | 2010-11-18 | ||
| US201161510653P | 2011-07-22 | 2011-07-22 | |
| US201161510648P | 2011-07-22 | 2011-07-22 | |
| US201161510660P | 2011-07-22 | 2011-07-22 | |
| US61/510,648 | 2011-07-22 | ||
| US61/510,653 | 2011-07-22 | ||
| US61/510,660 | 2011-07-22 | ||
| PCT/US2011/061440 WO2012068483A1 (en) | 2010-11-18 | 2011-11-18 | Preselection of subjects for therapeutic treatment based on hypoxic status |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014503499A JP2014503499A (ja) | 2014-02-13 |
| JP2014503499A5 true JP2014503499A5 (https=) | 2015-01-15 |
Family
ID=45217699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013540060A Pending JP2014503499A (ja) | 2010-11-18 | 2011-11-18 | 低酸素状態に基づく治療に適した被験体の事前選択 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20120128665A1 (https=) |
| EP (1) | EP2640385A1 (https=) |
| JP (1) | JP2014503499A (https=) |
| CN (1) | CN103327976A (https=) |
| AU (1) | AU2011329681A1 (https=) |
| CA (1) | CA2817564A1 (https=) |
| WO (1) | WO2012068483A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2035396B1 (en) | 2006-05-25 | 2014-05-14 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| US8106083B2 (en) | 2008-08-08 | 2012-01-31 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate HSP90 activity |
| US9205086B2 (en) | 2010-04-19 | 2015-12-08 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor |
| AU2012332424A1 (en) | 2011-11-02 | 2014-06-05 | Synta Pharmaceuticals Corp. | Combination therapy of Hsp90 inhibitors with platinum-containing agents |
| EP2773345A1 (en) | 2011-11-02 | 2014-09-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
| WO2013074594A1 (en) | 2011-11-14 | 2013-05-23 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with braf inhibitors |
| WO2013170182A1 (en) * | 2012-05-11 | 2013-11-14 | Synta Pharmaceuticals Corp. | Treating cancer with an hsp90 inhibitory compound |
| WO2013173436A1 (en) * | 2012-05-16 | 2013-11-21 | Synta Pharmaceuticals Corp. | Pre-selection of subjects for therapeutic treatment with an hsp90 inhibitor based on hypoxic status |
| US20160022757A1 (en) * | 2013-03-15 | 2016-01-28 | Icahn School Of Medicine At Mount Sinai | Therapeutic methods for treating solid tumors and related diagnostic methods |
| KR20160089528A (ko) * | 2013-12-12 | 2016-07-27 | 더 브리검 앤드 우먼즈 하스피털, 인크. | 신경퇴행성 질환의 치료 |
| TW201618773A (zh) | 2014-08-11 | 2016-06-01 | 艾森塔製藥公司 | Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物 |
| US20170239351A1 (en) | 2014-08-11 | 2017-08-24 | Acerta Pharma B.V. | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor |
| MA40596B1 (fr) | 2014-08-11 | 2021-12-31 | Acerta Pharma Bv | Combinaisons thérapeutiques d'un inhibiteur de btk et d'un inhibiteur de bcl-2 |
| CN104267191B (zh) * | 2014-09-09 | 2016-03-23 | 北京大学口腔医学院 | 口腔鳞状细胞癌的生物标志物及其应用 |
| WO2016073669A1 (en) * | 2014-11-05 | 2016-05-12 | Vojo Vukovic | Combination therapy of hsp90 inhibitory compounds with mtor inhibitors |
| US20190038209A1 (en) * | 2016-02-01 | 2019-02-07 | Board Of Regents, The University Of Texas System | Using Spectral CT to Diagnose Thyroid Nodules |
| CN105709239A (zh) * | 2016-03-22 | 2016-06-29 | 山东省肿瘤医院 | 一种非小细胞肺癌放疗相关的HIF-1α的抑制剂 |
| JPWO2023276768A1 (https=) * | 2021-06-29 | 2023-01-05 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4250255A (en) | 1977-07-11 | 1981-02-10 | Eastman Kodak Company | Assay method for isoenzyme activity |
| US6242208B1 (en) | 1988-07-15 | 2001-06-05 | International Reagents Corporation | LDH1 assay |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| CO4950519A1 (es) | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| US7087613B2 (en) | 1999-11-11 | 2006-08-08 | Osi Pharmaceuticals, Inc. | Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride |
| UA74803C2 (uk) | 1999-11-11 | 2006-02-15 | Осі Фармасьютікалз, Інк. | Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування |
| MXPA05011296A (es) | 2003-04-25 | 2006-01-24 | Gilead Sciences Inc | Conjugados de fosfonato inhibidores de la cinasa. |
| WO2006055760A1 (en) | 2004-11-18 | 2006-05-26 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| EP2007358A4 (en) * | 2006-04-04 | 2012-01-25 | Stc Unm | INFLATING PARTICLES FOR THE ADMINISTRATION OF A MEDICINAL PRODUCT |
| GB0610925D0 (en) * | 2006-06-02 | 2006-07-12 | Novartis Ag | Use of vascular endothelial growth factor receptor inhibitors for the treatment of cancer |
| SE530596C2 (sv) | 2006-10-13 | 2008-07-15 | Mathias Karlsson | Metod att fastställa syrebrist i blod från skalpen under förlossning |
| CA2670134A1 (en) | 2006-11-21 | 2008-08-28 | Beth Israel Deaconess Medical Center | Hypoxia related genes and proteins for the treatment and diagnosis of pregnancy related complications |
| US20080318241A1 (en) * | 2007-06-18 | 2008-12-25 | The Regents Of The University Of Michigan | Methods and Systems for Detecting Antiangiogenesis |
-
2011
- 2011-11-18 JP JP2013540060A patent/JP2014503499A/ja active Pending
- 2011-11-18 AU AU2011329681A patent/AU2011329681A1/en not_active Abandoned
- 2011-11-18 US US13/300,221 patent/US20120128665A1/en not_active Abandoned
- 2011-11-18 CN CN2011800653411A patent/CN103327976A/zh active Pending
- 2011-11-18 WO PCT/US2011/061440 patent/WO2012068483A1/en not_active Ceased
- 2011-11-18 EP EP11793607.0A patent/EP2640385A1/en not_active Withdrawn
- 2011-11-18 CA CA2817564A patent/CA2817564A1/en not_active Abandoned
-
2013
- 2013-12-17 US US14/109,543 patent/US20140178366A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014503499A5 (https=) | ||
| JP2014503500A5 (https=) | ||
| JP2013545759A5 (https=) | ||
| JP7793556B2 (ja) | 抗体－薬物コンジュゲートとａｔｒ阻害剤との組み合わせ | |
| KR101941758B1 (ko) | 항 trop2 항체-약물 컨쥬게이트 | |
| AU2017205101B2 (en) | Inhibitors of ataxia-telangiectasia mutated and Rad3-related protein kinase (ATR) for use in methods of treating cancer | |
| Varey et al. | VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro-and antiangiogenic VEGF-A isoforms has implications for therapy | |
| JP6066421B2 (ja) | 癌の治療のための低酸素活性化プロドラッグおよび血管新生阻害剤の投与方法 | |
| JPWO2020130125A1 (ja) | 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ | |
| AU2015317327B9 (en) | Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | |
| Speranza et al. | BKM-120 (Buparlisib): A phosphatidyl-inositol-3 kinase inhibitor with anti-invasive properties in glioblastoma | |
| KR20240130087A (ko) | 항체-약물 접합체와 atr 저해제의 조합 | |
| US20230372527A1 (en) | Combination of antibody-drug conjugate and parp1 selective inhibitor | |
| JP2013543011A (ja) | 癌の治療法 | |
| WO2015104292A2 (en) | Compounds for use in treating or preventing cancerous diseases | |
| RU2015105786A (ru) | Комбинированная терапия ингибиторами igf1r и pi3k | |
| JP2017526662A5 (https=) | ||
| TW202543645A (zh) | 抗癌組合治療 | |
| JP2014513097A5 (https=) | ||
| Brandl et al. | Targeting c-MYC through Interference with NAMPT and SIRT1 and their association to oncogenic drivers in murine serrated intestinal tumorigenesis | |
| US9844552B2 (en) | Methods of treating fibrosis | |
| JP2018528949A5 (https=) | ||
| Couderc et al. | Targeting the PI3K/mTOR pathway in murine endocrine cell lines: in vitro and in vivo effects on tumor cell growth | |
| Li et al. | XHL11, a novel selective EGFR inhibitor, overcomes EGFRT790M-mediated resistance in non-small cell lung cancer | |
| JP2019014685A (ja) | 抗がん剤 |